Another study found that geniposide could improve the symptoms of type 2 diabetes, and a single injection of geniposide (50 μM, 10 μL) into the lateral ventricle of STZ-induced AD rats could effectively reduce approximately 40% of spatial learning defects, downregulating the level of tau phosphorylation by approximately 30%. The gene discussed is MAPT; the disease is Alzheimer disease.